Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | March 29, 2018 | April 02, 2018 |
| WELLS FARGO & COMPANY/MNWFC · Entity 2824 | Director | April 01, 2013 | April 02, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date March 29, 2018 · Filed April 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 27,375.7941 |
Reported balance
After 2018-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-29 · Grant · Acquired 205.4266 · Balance 27,375.7941 F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.
F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.
F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.
WELLS FARGO & COMPANY/MN
Report date April 01, 2013 · Filed April 02, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 61,962.9483 |
Reported balance
After 2013-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2013-04-01 · Grant · Acquired 1,651.7736 · Balance 61,962.9483 F2: Conversion price is 1-for-1 F3: Deferred compensation shares payable in installments depending upon director's election. |
| Common Stock, $1 2/3 Par ValueSEC Table I · non-derivative | Direct | 1,122.938 |
Reported balance
Holding disclosure · report date 2013-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,122.938 F1: Includes 7.866 shares acquired through Wells Fargo & Company's dividend reinvestment plan on 3/1/2013. |
| Common Stock, $1 2/3 Par ValueSEC Table I · non-derivative | IndirectThrough Family Trust | 1,000 |
Reported balance
Holding disclosure · report date 2013-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 7.866 shares acquired through Wells Fargo & Company's dividend reinvestment plan on 3/1/2013.
F2: Conversion price is 1-for-1
F3: Deferred compensation shares payable in installments depending upon director's election.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2018 Filed Apr 2, 2018 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 205.4266 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-013416 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,375.7941 Underlying: Common Stock · 205.4266 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 01:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 178 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010264 · form4.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,170 Underlying: Common Stock · 178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F2 · shares: An aggregate of 178.180639 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 0.180639 was paid out in cash in connection with the conversion into shares of common stock. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 01:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010264 · form4.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 23:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 194.8116 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-000220 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,348.5481 Underlying: Common Stock · 194.8116 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| September 28, 2017 Filed Oct 3, 2017 00:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 173.3998 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-028708 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,153.7366 Underlying: Common Stock · 173.3998 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 953 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-023025 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,980.3368 Underlying: Common Stock · 953 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 29, 2017 Filed Jul 3, 2017 17:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 189.6079 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-022502 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,027.3368 Underlying: Common Stock · 189.6079 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 21:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017998 · form4.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,377 Underlying: Common Stock · 2,241 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 10, 2017 Filed May 12, 2017 21:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 10,376 | $0.00 Strike: $66.92 | $0.00 |
DisclosureSEC source: 0001127602-17-017998 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 Underlying: Common Stock · 10,376 shares Expires 2027-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 22:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 197.4375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-013645 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,837.7288 Underlying: Common Stock · 197.4375 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 173 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-17-010300 · form4.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,640 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F2 · shares: An aggregate of 173.167681 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 0.167681 was paid out in cash in connection with the conversion into shares of common stock. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010300 · form4.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| December 29, 2016 Filed Jan 4, 2017 00:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 167.1119 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-000368 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,813.459 Underlying: Common Stock · 167.1119 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| November 21, 2016 Filed Nov 29, 2016 19:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-068568 · form4.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,882 F1 · shares: Shares gifted to a charitable fund Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 23:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 153.8846 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-063782 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,646.3472 Underlying: Common Stock · 153.8846 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 21:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 795 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-057638 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,492.4625 Underlying: Common Stock · 795 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 29, 2016 Filed Jul 1, 2016 17:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 140.2926 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-056783 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,697.4625 Underlying: Common Stock · 140.2926 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,321 | $0.00 Strike: $83.90 | $0.00 |
DisclosureSEC source: 0001127602-16-052226 · form4.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,321 Underlying: Common Stock · 7,321 shares Expires 2026-05-11 F3 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-052226 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,136 Underlying: Common Stock · 1,787 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| March 30, 2016 Filed Apr 1, 2016 19:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 114.2812 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-048095 · form4.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,557.1699 Underlying: Common Stock · 114.2812 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 19:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 169 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-16-044737 · form4.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,443 Underlying: Common Stock · 169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F3 · shares: An aggregate of 169.251544 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 0.251544 was paid out in cash in connection with the conversion into shares of common stock. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 19:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-044737 · form4.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| December 30, 2015 Filed Jan 4, 2016 23:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 103.1604 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-016961 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,612.1403 Underlying: Common Stock · 103.1604 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| September 29, 2015 Filed Oct 1, 2015 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 109.2903 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-013512 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,508.98 Underlying: Common Stock · 109.2903 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 581 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-010921 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,399.6897 Underlying: Common Stock · 581 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 29, 2015 Filed Jul 1, 2015 22:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 88.381 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-010625 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,818.6897 Underlying: Common Stock · 88.381 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007269 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,349 Underlying: Common Stock · 1,466 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 5,167 | $0.00 Strike: $102.27 | $0.00 |
DisclosureSEC source: 0001179110-15-007269 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,167 Underlying: Common Stock · 5,167 shares Expires 2025-05-06 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| March 01, 2015 Filed Mar 3, 2015 21:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-003910 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,728 Underlying: Common Stock · 167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F3 · shares: An aggregate of 167.168 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 0.168 was paid out in cash in connection with the conversion into shares of common stock. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2015 Filed Mar 3, 2015 21:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-003910 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 16:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 45,000 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001179110-14-012139 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 16:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 45,000 | $90.56 | $4,075,402.50 |
DisclosureSEC source: 0001179110-14-012139 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F2 · price: Sale prices reported for the transactions reported here range from $90.525 to $90.605. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 16:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 45,000 | $26.62 | $1,197,675.00 |
DisclosureSEC source: 0001179110-14-012139 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 20:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-011276 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,895 Underlying: Common Stock · 791 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 07, 2014 Filed May 9, 2014 00:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008017 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,883 Underlying: Common Stock · 1,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 07, 2014 Filed May 9, 2014 00:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 4,868 | $0.00 Strike: $78.77 | $0.00 |
DisclosureSEC source: 0001179110-14-008017 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,868 Underlying: Common Stock · 4,868 shares Expires 2024-05-07 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| March 01, 2014 Filed Mar 4, 2014 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-004382 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,104 Underlying: Common Stock · 167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F3 · shares: An aggregate of 167.168 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 0.168 was paid out in cash in connection with the conversion into shares of common stock. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2014 Filed Mar 4, 2014 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-004382 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| February 26, 2014 Filed Feb 28, 2014 17:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001179110-14-003908 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 45,000 Underlying: Common Stock · 20,000 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| February 26, 2014 Filed Feb 28, 2014 17:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 20,000 | $84.05 | $1,681,070.00 |
DisclosureSEC source: 0001179110-14-003908 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F2 · price: Sale prices reported for the transactions reported here range from $83.86 to $84.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 26, 2014 Filed Feb 28, 2014 17:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $26.62 | $532,300.00 |
DisclosureSEC source: 0001179110-14-003908 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2014 Filed Feb 21, 2014 19:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 19,068 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001179110-14-003304 · edgar.xml · derivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 19,068 shares Expires 2019-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| February 19, 2014 Filed Feb 21, 2014 19:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,892 | $82.89 | $985,733.83 |
DisclosureSEC source: 0001179110-14-003304 · edgar.xml · nonDerivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F3 · price: Sale prices reported for the transactions reported here range from $82.35 to $83.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 19, 2014 Filed Feb 21, 2014 19:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,176 | $83.51 | $599,256.28 |
DisclosureSEC source: 0001179110-14-003304 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,892 F2 · price: Sale prices reported for the transactions reported here range from $83.35 to $83.79. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 19, 2014 Filed Feb 21, 2014 19:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 19,068 | $22.02 | $419,782.02 |
DisclosureSEC source: 0001179110-14-003304 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 19,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2014 Filed Feb 18, 2014 23:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 19,068 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001179110-14-003007 · edgar.xml · derivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 19,068 Underlying: Common Stock · 19,068 shares Expires 2019-05-06 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| February 14, 2014 Filed Feb 18, 2014 23:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 65,000 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001179110-14-003007 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2018-05-08 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| February 14, 2014 Filed Feb 18, 2014 23:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 19,068 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001179110-14-003007 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,068 shares Expires 2019-05-06 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| February 14, 2014 Filed Feb 18, 2014 23:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 65,000 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001179110-14-003007 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2018-05-08 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| August 30, 2013 Filed Sep 4, 2013 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 130,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-13-013834 · edgar.xml · derivative · entry 6 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 130,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.